This strategy, called ligandomics, is limited by the efficiency of immuno-precipitation, a large amount of tissue required (infeasible for pediatric brain tumors), the need for robust tumor cell MHC expression, the identification of relatively few peptides, low throughput, and reliance upon digestion free spectra searches resulting in a higher degree of false positives18,19. This evidence concerns the gene HLA-C and brain neoplasm.